Saved in:
Bibliographic Details
Main Authors: Qiyu Xie, Zhixin Liao, Hong Xu, Wai Yao, Xuming Chen, Xufeng Wan, Duan Wang, Zongke Zhou
Format: Artículo Open Access
Published: Wiley 2025
Subjects:
Online Access:https://onlinelibrary.wiley.com/doi/10.1111/os.70113
Tags: Add Tag
No Tags, Be the first to tag this record!
Table of Contents:
  • The Prognostic Role of Perioperative Dexamethasone in Aseptic Revision Hip Arthroplasty—A Retrospective Cohort Study Qiyu Xie Zhixin Liao Hong Xu Wai Yao Xuming Chen Xufeng Wan Duan Wang Zongke Zhou Orthopaedic Surgery ABSTRACTObjectiveAseptic hip revision arthroplasty often results in significant postoperative pain, inflammation, nausea, and vomiting. While perioperative dexamethasone has demonstrated benefits in primary hip arthroplasty, its efficacy and safety in revision procedures remain unclear. This study aims to evaluate the effects of perioperative dexamethasone on postoperative pain, inflammation, postoperative nausea and vomiting (PONV), and safety in aseptic hip revision.MethodsA retrospective cohort study was conducted on 414 patients undergoing aseptic hip revision arthroplasty between 2008 and 2023. Patients were categorized into two groups: those receiving dexamethasone perioperatively (n = 218) and a control group (n = 196). Outcomes included Visual Analog Scale (VAS) pain scores, inflammation markers including C‐reactive protein (CRP) and interleukin‐6 (IL‐6), PONV incidence, analgesic and antiemetic usage, length of stay (LOS), and postoperative complications. Independent samples t‐test or Mann–Whitney U test is applied to continuous variables based on normality, while chi‐square test or Fisher's exact test is used for categorical variables according to sample size.ResultsThe dexamethasone group (average dose: 12.67 mg) exhibited significantly lower VAS scores (p < 0.001) and reduced morphine use on postoperative days (PODs) 1–3. CRP (POD2: 40.60 mg/L vs. 111.66 mg/L) and IL‐6 levels (POD1: 31.85 pg/mL vs. 138.28 pg/mL) were significantly lower in the dexamethasone group (both p < 0.001). PONV incidence (28.4% vs. 40.81%) and antiemetic usage were reduced in the dexamethasone group. No significant differences were observed in LOS or postoperative complications between the two groups.ConclusionPerioperative low‐dose dexamethasone effectively mitigates pain, inflammation, and PONV in aseptic hip revision arthroplasty without increasing the risk of complications. 10.1111/os.70113 http://creativecommons.org/licenses/by-nc-nd/4.0/